We are live on ! Find out more
AXSM icon

Axsome Therapeutics

226 hedge funds and large institutions have $2.65B invested in Axsome Therapeutics in 2023 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 87 increasing their positions, 71 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more call options, than puts

Call options by funds: $56.4M | Put options by funds: $36.8M

25% more funds holding in top 10

Funds holding in top 10: 810 (+2)

23% more repeat investments, than reductions

Existing positions increased: 87 | Existing positions reduced: 71

2.14% more ownership

Funds ownership: 78.14%80.28% (+2.1%)

1% more capital invested

Capital invested by funds: $2.61B → $2.65B (+$33.4M)

7% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 28

2% less funds holding

Funds holding: 231226 (-5)

Holders
226
Holders Change
-5
Holders Change %
-2.16%
% of All Funds
3.59%
Holding in Top 10
10
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+25%
% of All Funds
0.16%
New
26
Increased
87
Reduced
71
Closed
28
Calls
$56.4M
Puts
$36.8M
Net Calls
+$19.5M
Net Calls Change
-$25.6M
Name Holding Trade Value Shares
Change
Change in
Stake
HighTower Advisors
251
HighTower Advisors
Illinois
-$199K -2,778 Closed
IPW
252
Impact Partnership Wealth
Georgia
-$1.08K -15 Closed
BIA
253
Bell Investment Advisors
California
-$935 -13 Closed

AXSM Hedge Fund Activity: Q3 2023 in Review

226 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q3 2023, worth a combined $2.65B — up 1.3% from $2.61B a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of AXSM and 26 opened new positions — a net loss of 2 holders — while 71 trimmed existing stakes and 87 added.

The largest buyer was Citadel Advisors, adding an estimated $62.9M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $24.4M sold.

  • 226 institutional investors held Axsome Therapeutics (AXSM) as of Q3 2023, down from 231 in Q2 2023.
  • Funds reported $2.65B of Axsome Therapeutics stock for Q3 2023, up 1.3% quarter-over-quarter.
  • 26 funds opened new Axsome Therapeutics positions in Q3 2023 and 28 closed out, a net change of -2 holders.
  • The largest Axsome Therapeutics buyer in Q3 2023 was Citadel Advisors, an estimated $62.9M added.
  • The largest Axsome Therapeutics seller in Q3 2023 was Cormorant Asset Management, an estimated $24.4M sold.

Based on aggregated 13F filings for Q3 2023.